Exceptional Response To Pembrolizumab For Treatment of Metastatic Chemorefractory Endometrial Carcinoma In A Patient With Lynch Syndrome: A Case Report

Authors

Samantha Batman
J Alejandro Rauh-Hain
Michaela Onstad Grinsfelder
Ross Harrison
Monica Avila
Han Cun
Jeffrey Andrew How
Nidhi Tandon
Xiaohong Wang
Emily Hinchcliff
Amir Anthony Jazaeri
Kathleen M Schmeler

Publication Date

1-1-2023

Journal

Case Reports in Oncology

Abstract

Advanced endometrial cancer is associated with poor outcomes and few treatment options exist. Recently, the US Federal Drug Administration approved pembrolizumab for the treatment of endometrial cancers that are deficient in mismatch repair and have high microsatellite instability (MSI). Lynch syndrome is an autosomal dominant disease that causes MSI-high endometrial cancer. We report a case of a 46-year-old woman with Lynch syndrome and advanced endometrial cancer who experienced progressive disease after treatment with chemotherapy with carboplatin and paclitaxel. She was then treated with single-agent pembrolizumab and had an exceptional response. She was noted to have a significant decrease in the size of a large uterine mass extending into the vagina and vulva, as well as decrease in the size of lymphadenopathy. Data are limited at this time for patients with Lynch syndrome treated with single-agent pembrolizumab. Our case report seeks to add to the body of literature that suggests that this patient population may particularly benefit from this novel therapy.

Keywords

Pembrolizumab, Advanced endometrial cancer, Lynch syndrome

DOI

10.1159/000530154

PMID

37123608

PMCID

PMC10134052

PubMedCentral® Posted Date

April 2023

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes